Remedies for prostatic hypertrophy
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 23, 2007
app pub date -
Mar 9, 2005
filing date -
Mar 12, 2004
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
A treatment and/or preventive agent for prostatic hypertrophy includes a compound having an antagonistic effect to an angiotensin II receptor, or a pharmaceutically acceptable salt or a prodrug thereof, as an active ingredient, wherein said compound having an antagonistic effect to an angiotensin II receptor is one or more compounds selected from the group consisting of losartan, potassium losartan, candesartan, candesartan cilexetil, balsartan, eprosartan, zolasartan, telmisartan, irbesartan, tasosartan, olmesartan medoxomil, and olmesartan.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully